Real-world effectiveness and safety of esketamine intranasal spray combined with treatment-as-usual in psychiatric inpatients
Introduction Esketamine intranasal spray has been approved in both the USA and EU as a novel treatment in patients with treatment-resistant major depression (TRD) and for the management of acute depressive emergencies during the course of major depressive disorder (MDD). Real-world data on the eff...
| الحاوية / القاعدة: | European Psychiatry |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
Cambridge University Press
2024-04-01
|
| الوصول للمادة أونلاين: | https://www.cambridge.org/core/product/identifier/S092493382400539X/type/journal_article |